ID   UHRF2_HUMAN             Reviewed;         802 AA.
AC   Q96PU4; Q5VYR1; Q5VYR3; Q659C8; Q8TAG7;
DT   07-JUN-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2001, sequence version 1.
DT   10-MAY-2017, entry version 147.
DE   RecName: Full=E3 ubiquitin-protein ligase UHRF2;
DE            EC=2.3.2.27;
DE   AltName: Full=Np95/ICBP90-like RING finger protein;
DE            Short=Np95-like RING finger protein;
DE   AltName: Full=Nuclear protein 97;
DE   AltName: Full=Nuclear zinc finger protein Np97;
DE   AltName: Full=RING finger protein 107;
DE   AltName: Full=RING-type E3 ubiquitin transferase UHRF2;
DE   AltName: Full=Ubiquitin-like PHD and RING finger domain-containing protein 2;
DE   AltName: Full=Ubiquitin-like-containing PHD and RING finger domains protein 2;
GN   Name=UHRF2; Synonyms=NIRF, RNF107;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), SUBCELLULAR LOCATION,
RP   INDUCTION, FUNCTION, AND INTERACTION WITH PCNP.
RC   TISSUE=Fetal brain;
RX   PubMed=12176013; DOI=10.1016/S0006-291X(02)00890-2;
RA   Mori T., Li Y., Hata H., Ono K., Kochi H.;
RT   "NIRF, a novel RING finger protein, is involved in cell-cycle
RT   regulation.";
RL   Biochem. Biophys. Res. Commun. 296:530-536(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Davenport J.W., Fernandes E.R., Neale G.A.M., Goorha R.M.;
RT   "LMO2-induced T cell leukemias overexpress a novel gene, Uhr1,
RT   containing RING and PHD zinc fingers and an ubiquitin-like domain.";
RL   Submitted (JUN-2000) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 636-802 (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [6]
RP   FUNCTION IN CELL CYCLE, PHOSPHORYLATION, INTERACTION WITH CDK2, AND
RP   IDENTIFICATION IN A COMPLEX WITH CDK2 AND CCNE1.
RX   PubMed=15178429; DOI=10.1016/j.bbrc.2004.04.190;
RA   Li Y., Mori T., Hata H., Homma Y., Kochi H.;
RT   "NIRF induces G1 arrest and associates with Cdk2.";
RL   Biochem. Biophys. Res. Commun. 319:464-468(2004).
RN   [7]
RP   UBIQUITINATION, INTERACTION WITH PCNP, AND FUNCTION.
RX   PubMed=14741369; DOI=10.1016/S0014-5793(03)01495-9;
RA   Mori T., Li Y., Hata H., Kochi H.;
RT   "NIRF is a ubiquitin ligase that is capable of ubiquitinating PCNP, a
RT   PEST-containing nuclear protein.";
RL   FEBS Lett. 557:209-214(2004).
RN   [8]
RP   FUNCTION, AND INTERACTION WITH HDAC1.
RX   PubMed=15361834; DOI=10.1038/sj.onc.1208053;
RA   Unoki M., Nishidate T., Nakamura Y.;
RT   "ICBP90, an E2F-1 target, recruits HDAC1 and binds to methyl-CpG
RT   through its SRA domain.";
RL   Oncogene 23:7601-7610(2004).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-667, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [11]
RP   FUNCTION, INTERACTION WITH CCDN1; CCNE1; TP53 AND RB1, AND ASSOCIATION
RP   WITH TUMORIGENESIS.
RX   PubMed=21952639; DOI=10.4161/cc.10.19.17176;
RA   Mori T., Ikeda D.D., Fukushima T., Takenoshita S., Kochi H.;
RT   "NIRF constitutes a nodal point in the cell cycle network and is a
RT   candidate tumor suppressor.";
RL   Cell Cycle 10:3284-3299(2011).
RN   [12]
RP   FUNCTION, AUTOSUMOYLATION, INTERACTION WITH UBE2I, SUBCELLULAR
RP   LOCATION, AND MUTAGENESIS OF LYS-307; LYS-548 AND CYS-735.
RX   PubMed=23404503; DOI=10.1074/jbc.M112.438234;
RA   Oh Y., Chung K.C.;
RT   "UHRF2, a ubiquitin E3 ligase, acts as a small ubiquitin-like modifier
RT   E3 ligase for zinc finger protein 131.";
RL   J. Biol. Chem. 288:9102-9111(2013).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [14]
RP   STRUCTURE BY NMR OF 1-76.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the N-terminal ubiquitin-like domain in human
RT   NP95/ICBP90-like RING finger protein (NIRF).";
RL   Submitted (AUG-2005) to the PDB data bank.
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 672-802 IN COMPLEX WITH ZINC
RP   IONS.
RG   Structural genomics consortium (SGC);
RT   "2.1 Angstrom crystal structure of the human ubiquitin ligase NIRF.";
RL   Submitted (JAN-2006) to the PDB data bank.
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 672-802, SUBUNIT, AND
RP   DISULFIDE BOND.
RG   Structural genomics consortium (SGC);
RT   "2.1 Angstrom crystal structure of the human ubiquitin ligase NIRF.";
RL   Submitted (FEB-2009) to the PDB data bank.
RN   [17]
RP   VARIANT [LARGE SCALE ANALYSIS] ASN-87.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: E3 ubiquitin-protein ligase that is an intermolecular
CC       hub protein in the cell cycle network. Through cooperative DNA and
CC       histone binding, may contribute to a tighter epigenetic control of
CC       gene expression in differentiated cells. Ubiquitinates cyclins,
CC       CCND1 and CCNE1, in an apparently phosphorylation-independent
CC       manner and induces G1 arrest. Also ubiquitinates PCNP leading to
CC       its degradation by the proteasome. E3 SUMO-, but not ubiquitin-,
CC       protein ligase for ZNF131. {ECO:0000269|PubMed:12176013,
CC       ECO:0000269|PubMed:14741369, ECO:0000269|PubMed:15178429,
CC       ECO:0000269|PubMed:15361834, ECO:0000269|PubMed:21952639,
CC       ECO:0000269|PubMed:23404503}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugating
CC       enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-
CC       conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor
CC       protein]-L-lysine.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Homodimer; disulfide-linked. Binds methylated CpG
CC       containing oligonucleotides. Interacts with H3: the interaction
CC       has a preference for the 'Lys-9' trimethylated form of H3
CC       (H3K9me3) (By similarity). Interacts with PCNP, HDAC1 and CDK2
CC       (inactive form). Component of a complex at least composed of
CC       UHRF2, CDK2 and CCNE1. Interacts directly with CCNE1; the
CC       interaction ubiquitinates CCNE1 and appears independent of CCNE1
CC       phosphorylation. Interacts with CCND1; the interaction
CC       ubiquitinates CCND1 and appears independent of CCND1
CC       phosphorylation. Interacts with p53/TP53 and RB1. Interacts with
CC       UBE2I. {ECO:0000250, ECO:0000269|PubMed:12176013,
CC       ECO:0000269|PubMed:14741369, ECO:0000269|PubMed:15178429,
CC       ECO:0000269|PubMed:15361834, ECO:0000269|PubMed:21952639,
CC       ECO:0000269|PubMed:23404503, ECO:0000269|Ref.15,
CC       ECO:0000269|Ref.16}.
CC   -!- INTERACTION:
CC       P20248:CCNA2; NbExp=2; IntAct=EBI-625304, EBI-457097;
CC       P14635:CCNB1; NbExp=2; IntAct=EBI-625304, EBI-495332;
CC       P24385:CCND1; NbExp=4; IntAct=EBI-625304, EBI-375001;
CC       P24864:CCNE1; NbExp=4; IntAct=EBI-625304, EBI-519526;
CC       P24941:CDK2; NbExp=5; IntAct=EBI-625304, EBI-375096;
CC       P06400:RB1; NbExp=4; IntAct=EBI-625304, EBI-491274;
CC       P04637:TP53; NbExp=3; IntAct=EBI-625304, EBI-366083;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-
CC       ProRule:PRU00358, ECO:0000269|PubMed:12176013,
CC       ECO:0000269|PubMed:23404503}. Note=Enriched at pericentric
CC       heterochromatin (PH). This localization is dependent on the
CC       interaction with H3K9me3 (By similarity). {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q96PU4-1; Sequence=Displayed;
CC       Name=2; Synonyms=a;
CC         IsoId=Q96PU4-2; Sequence=VSP_013874, VSP_013875;
CC         Note=No experimental confirmation available.;
CC   -!- INDUCTION: Up-regulated in proliferating fetal lung fibroblasts
CC       and in U-937 myeloid leukemia cells. Down-regulated in these cells
CC       by growth arrest and differentiation. In other cell types which
CC       cannot leave the cell cycle, such as tumoral HT-1080 and Hep-G2,
CC       levels are consistently up-regulated.
CC       {ECO:0000269|PubMed:12176013}.
CC   -!- PTM: May be autoubiquitinated; which may lead to proteasomal
CC       degradation. {ECO:0000269|PubMed:14741369}.
CC   -!- PTM: Phosphorylated. Phosphorylation may be mediated by CDK2.
CC       {ECO:0000269|PubMed:15178429}.
CC   -!- PTM: Autosumoylated.
CC   -!- DISEASE: Note=Associated with various cancers. DNA copy number
CC       loss is found in multiple kinds of malignancies originating from
CC       the brain, breast, stomach, kidney, hematopoietic tissue and lung.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAH74120.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=CAI13295.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB071698; BAB68317.1; -; mRNA.
DR   EMBL; AF274049; AAM33799.1; -; mRNA.
DR   EMBL; AL353718; CAH74119.1; -; Genomic_DNA.
DR   EMBL; AL133480; CAH74119.1; JOINED; Genomic_DNA.
DR   EMBL; AL133480; CAI13293.1; -; Genomic_DNA.
DR   EMBL; AL353718; CAI13293.1; JOINED; Genomic_DNA.
DR   EMBL; AL353718; CAH74120.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AL133480; CAH74120.1; JOINED; Genomic_DNA.
DR   EMBL; AL133480; CAI13295.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AL353718; CAI13295.1; JOINED; Genomic_DNA.
DR   EMBL; BC028397; AAH28397.1; -; mRNA.
DR   EMBL; AL137728; CAH56383.1; -; mRNA.
DR   CCDS; CCDS6469.1; -. [Q96PU4-1]
DR   RefSeq; NP_690856.1; NM_152896.2. [Q96PU4-1]
DR   UniGene; Hs.493401; -.
DR   PDB; 1WY8; NMR; -; A=1-76.
DR   PDB; 1Z6U; X-ray; 2.10 A; A/B=672-802.
DR   PDB; 2E6S; NMR; -; A=326-395.
DR   PDB; 3OLN; X-ray; 2.30 A; A/B=419-648.
DR   PDB; 4PW5; X-ray; 2.20 A; A/B/E/F=419-648.
DR   PDB; 4PW6; X-ray; 3.79 A; A/B=419-648.
DR   PDB; 4PW7; X-ray; 2.00 A; A/B/E/F=419-648.
DR   PDB; 4TVR; X-ray; 2.29 A; A=109-395.
DR   PDBsum; 1WY8; -.
DR   PDBsum; 1Z6U; -.
DR   PDBsum; 2E6S; -.
DR   PDBsum; 3OLN; -.
DR   PDBsum; 4PW5; -.
DR   PDBsum; 4PW6; -.
DR   PDBsum; 4PW7; -.
DR   PDBsum; 4TVR; -.
DR   ProteinModelPortal; Q96PU4; -.
DR   SMR; Q96PU4; -.
DR   BioGrid; 125434; 58.
DR   IntAct; Q96PU4; 38.
DR   MINT; MINT-1196856; -.
DR   STRING; 9606.ENSP00000276893; -.
DR   iPTMnet; Q96PU4; -.
DR   PhosphoSitePlus; Q96PU4; -.
DR   BioMuta; UHRF2; -.
DR   DMDM; 67462076; -.
DR   EPD; Q96PU4; -.
DR   MaxQB; Q96PU4; -.
DR   PaxDb; Q96PU4; -.
DR   PeptideAtlas; Q96PU4; -.
DR   PRIDE; Q96PU4; -.
DR   DNASU; 115426; -.
DR   Ensembl; ENST00000276893; ENSP00000276893; ENSG00000147854. [Q96PU4-1]
DR   Ensembl; ENST00000468435; ENSP00000434182; ENSG00000147854. [Q96PU4-2]
DR   GeneID; 115426; -.
DR   KEGG; hsa:115426; -.
DR   UCSC; uc003zjy.4; human. [Q96PU4-1]
DR   CTD; 115426; -.
DR   DisGeNET; 115426; -.
DR   GeneCards; UHRF2; -.
DR   HGNC; HGNC:12557; UHRF2.
DR   HPA; HPA026633; -.
DR   HPA; HPA026697; -.
DR   MIM; 615211; gene.
DR   neXtProt; NX_Q96PU4; -.
DR   OpenTargets; ENSG00000147854; -.
DR   PharmGKB; PA37197; -.
DR   eggNOG; ENOG410IFAP; Eukaryota.
DR   eggNOG; COG3440; LUCA.
DR   GeneTree; ENSGT00390000008296; -.
DR   HOGENOM; HOG000124662; -.
DR   HOVERGEN; HBG059298; -.
DR   InParanoid; Q96PU4; -.
DR   KO; K15713; -.
DR   OMA; CRFCSCC; -.
DR   OrthoDB; EOG091G06BT; -.
DR   PhylomeDB; Q96PU4; -.
DR   TreeFam; TF106434; -.
DR   UniPathway; UPA00143; -.
DR   ChiTaRS; UHRF2; human.
DR   EvolutionaryTrace; Q96PU4; -.
DR   GeneWiki; UHRF2; -.
DR   GenomeRNAi; 115426; -.
DR   PRO; PR:Q96PU4; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; ENSG00000147854; -.
DR   CleanEx; HS_UHRF2; -.
DR   ExpressionAtlas; Q96PU4; baseline and differential.
DR   Genevisible; Q96PU4; HS.
DR   GO; GO:0005720; C:nuclear heterochromatin; ISS:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:HGNC.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0042393; F:histone binding; ISS:UniProtKB.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IDA:MGI.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:HGNC.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0030154; P:cell differentiation; IEP:HGNC.
DR   GO; GO:0008283; P:cell proliferation; IEP:HGNC.
DR   GO; GO:0010216; P:maintenance of DNA methylation; IBA:GO_Central.
DR   GO; GO:0071158; P:positive regulation of cell cycle arrest; IDA:UniProtKB.
DR   GO; GO:0051865; P:protein autoubiquitination; IDA:HGNC.
DR   GO; GO:0016567; P:protein ubiquitination; IDA:HGNC.
DR   GO; GO:0051726; P:regulation of cell cycle; TAS:HGNC.
DR   GO; GO:0090308; P:regulation of methylation-dependent chromatin silencing; IBA:GO_Central.
DR   CDD; cd00162; RING; 1.
DR   Gene3D; 2.30.280.10; -; 1.
DR   Gene3D; 2.30.30.30; -; 1.
DR   Gene3D; 3.30.40.10; -; 2.
DR   InterPro; IPR015947; PUA-like_domain.
DR   InterPro; IPR014722; Rib_L2_dom2.
DR   InterPro; IPR003105; SRA_YDG.
DR   InterPro; IPR021991; TTD_dom.
DR   InterPro; IPR029071; Ubiquitin-rel_dom.
DR   InterPro; IPR000626; Ubiquitin_dom.
DR   InterPro; IPR011011; Znf_FYVE_PHD.
DR   InterPro; IPR001965; Znf_PHD.
DR   InterPro; IPR019787; Znf_PHD-finger.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   InterPro; IPR017907; Znf_RING_CS.
DR   Pfam; PF00628; PHD; 1.
DR   Pfam; PF02182; SAD_SRA; 1.
DR   Pfam; PF12148; TTD; 1.
DR   Pfam; PF00240; ubiquitin; 1.
DR   SMART; SM00249; PHD; 1.
DR   SMART; SM00184; RING; 2.
DR   SMART; SM00466; SRA; 1.
DR   SMART; SM00213; UBQ; 1.
DR   SUPFAM; SSF54236; SSF54236; 1.
DR   SUPFAM; SSF57903; SSF57903; 1.
DR   SUPFAM; SSF88697; SSF88697; 1.
DR   PROSITE; PS50053; UBIQUITIN_2; 1.
DR   PROSITE; PS51015; YDG; 1.
DR   PROSITE; PS01359; ZF_PHD_1; 1.
DR   PROSITE; PS50016; ZF_PHD_2; 1.
DR   PROSITE; PS00518; ZF_RING_1; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell cycle; Complete proteome;
KW   Disulfide bond; DNA-binding; Metal-binding; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; Transferase; Ubl conjugation;
KW   Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN         1    802       E3 ubiquitin-protein ligase UHRF2.
FT                                /FTId=PRO_0000056147.
FT   DOMAIN        1     78       Ubiquitin-like. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00214}.
FT   DOMAIN      448    612       YDG. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00358}.
FT   ZN_FING     344    395       PHD-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00146}.
FT   ZN_FING     733    772       RING-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00175}.
FT   REGION      117    311       Required for interaction with histone H3.
FT                                {ECO:0000250}.
FT   REGION      194    288       Interaction with PCNP.
FT   REGION      414    644       Methyl-CpG binding and interaction with
FT                                HDAC1. {ECO:0000269|PubMed:15361834}.
FT   MOD_RES     667    667       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   DISULFID    704    704       Interchain. {ECO:0000269|Ref.16}.
FT   VAR_SEQ     500    503       DRGD -> LTEL (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_013874.
FT   VAR_SEQ     504    802       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_013875.
FT   VARIANT      87     87       I -> N (in a colorectal cancer sample;
FT                                somatic mutation; dbSNP:rs147971931).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_035961.
FT   MUTAGEN     307    307       K->R: No effect on autosumoylation.
FT                                {ECO:0000269|PubMed:23404503}.
FT   MUTAGEN     548    548       K->R: No effect on autosumoylation.
FT                                {ECO:0000269|PubMed:23404503}.
FT   MUTAGEN     735    735       C->S: No effect on autosumoylation, nor
FT                                on ZNF131 sumoylation.
FT                                {ECO:0000269|PubMed:23404503}.
FT   CONFLICT    287    287       L -> M (in Ref. 4; AAH28397).
FT                                {ECO:0000305}.
FT   CONFLICT    329    329       P -> T (in Ref. 4; AAH28397).
FT                                {ECO:0000305}.
FT   CONFLICT    416    416       P -> Q (in Ref. 4; AAH28397).
FT                                {ECO:0000305}.
FT   STRAND        1      7       {ECO:0000244|PDB:1WY8}.
FT   STRAND       13     19       {ECO:0000244|PDB:1WY8}.
FT   HELIX        25     35       {ECO:0000244|PDB:1WY8}.
FT   TURN         40     42       {ECO:0000244|PDB:1WY8}.
FT   STRAND       43     47       {ECO:0000244|PDB:1WY8}.
FT   STRAND       54     57       {ECO:0000244|PDB:1WY8}.
FT   HELIX        58     61       {ECO:0000244|PDB:1WY8}.
FT   STRAND       68     73       {ECO:0000244|PDB:1WY8}.
FT   STRAND      132    136       {ECO:0000244|PDB:4TVR}.
FT   TURN        138    140       {ECO:0000244|PDB:4TVR}.
FT   STRAND      143    153       {ECO:0000244|PDB:4TVR}.
FT   STRAND      206    213       {ECO:0000244|PDB:4TVR}.
FT   HELIX       217    219       {ECO:0000244|PDB:4TVR}.
FT   STRAND      222    224       {ECO:0000244|PDB:4TVR}.
FT   HELIX       226    228       {ECO:0000244|PDB:4TVR}.
FT   STRAND      229    231       {ECO:0000244|PDB:4TVR}.
FT   HELIX       239    241       {ECO:0000244|PDB:4TVR}.
FT   STRAND      247    252       {ECO:0000244|PDB:4TVR}.
FT   STRAND      262    273       {ECO:0000244|PDB:4TVR}.
FT   STRAND      275    277       {ECO:0000244|PDB:4TVR}.
FT   STRAND      279    286       {ECO:0000244|PDB:4TVR}.
FT   STRAND      293    298       {ECO:0000244|PDB:4TVR}.
FT   TURN        318    320       {ECO:0000244|PDB:4TVR}.
FT   TURN        332    336       {ECO:0000244|PDB:4TVR}.
FT   STRAND      338    340       {ECO:0000244|PDB:4TVR}.
FT   TURN        343    345       {ECO:0000244|PDB:4TVR}.
FT   TURN        348    350       {ECO:0000244|PDB:4TVR}.
FT   STRAND      356    360       {ECO:0000244|PDB:4TVR}.
FT   STRAND      363    365       {ECO:0000244|PDB:4TVR}.
FT   STRAND      368    370       {ECO:0000244|PDB:4TVR}.
FT   TURN        371    373       {ECO:0000244|PDB:4TVR}.
FT   STRAND      374    376       {ECO:0000244|PDB:4TVR}.
FT   TURN        390    392       {ECO:0000244|PDB:4TVR}.
FT   STRAND      458    461       {ECO:0000244|PDB:4PW7}.
FT   HELIX       462    467       {ECO:0000244|PDB:4PW7}.
FT   STRAND      477    481       {ECO:0000244|PDB:4PW7}.
FT   TURN        482    484       {ECO:0000244|PDB:4PW7}.
FT   STRAND      485    491       {ECO:0000244|PDB:4PW7}.
FT   STRAND      502    508       {ECO:0000244|PDB:4PW7}.
FT   HELIX       532    539       {ECO:0000244|PDB:4PW7}.
FT   STRAND      541    543       {ECO:0000244|PDB:4PW7}.
FT   TURN        547    549       {ECO:0000244|PDB:4PW7}.
FT   HELIX       556    558       {ECO:0000244|PDB:4PW7}.
FT   STRAND      562    567       {ECO:0000244|PDB:4PW7}.
FT   HELIX       568    572       {ECO:0000244|PDB:4PW7}.
FT   STRAND      575    577       {ECO:0000244|PDB:4PW7}.
FT   STRAND      579    597       {ECO:0000244|PDB:4PW7}.
FT   TURN        599    601       {ECO:0000244|PDB:4PW7}.
FT   STRAND      602    612       {ECO:0000244|PDB:4PW7}.
FT   HELIX       622    630       {ECO:0000244|PDB:4PW7}.
FT   HELIX       694    702       {ECO:0000244|PDB:1Z6U}.
FT   HELIX       704    706       {ECO:0000244|PDB:1Z6U}.
FT   HELIX       707    713       {ECO:0000244|PDB:1Z6U}.
FT   HELIX       714    722       {ECO:0000244|PDB:1Z6U}.
FT   HELIX       723    730       {ECO:0000244|PDB:1Z6U}.
FT   TURN        734    736       {ECO:0000244|PDB:1Z6U}.
FT   STRAND      737    739       {ECO:0000244|PDB:1Z6U}.
FT   STRAND      741    745       {ECO:0000244|PDB:1Z6U}.
FT   STRAND      751    753       {ECO:0000244|PDB:1Z6U}.
FT   HELIX       754    762       {ECO:0000244|PDB:1Z6U}.
FT   TURN        769    771       {ECO:0000244|PDB:1Z6U}.
FT   HELIX       785    794       {ECO:0000244|PDB:1Z6U}.
FT   TURN        796    801       {ECO:0000244|PDB:1Z6U}.
SQ   SEQUENCE   802 AA;  89985 MW;  190E26D5A347A7FA CRC64;
     MWIQVRTIDG SKTCTIEDVS RKATIEELRE RVWALFDVRP ECQRLFYRGK QLENGYTLFD
     YDVGLNDIIQ LLVRPDPDHL PGTSTQIEAK PCSNSPPKVK KAPRVGPSNQ PSTSARARLI
     DPGFGIYKVN ELVDARDVGL GAWFEAHIHS VTRASDGQSR GKTPLKNGSS CKRTNGNIKH
     KSKENTNKLD SVPSTSNSDC VAADEDVIYH IQYDEYPESG TLEMNVKDLR PRARTILKWN
     ELNVGDVVMV NYNVESPGQR GFWFDAEITT LKTISRTKKE LRVKIFLGGS EGTLNDCKII
     SVDEIFKIER PGAHPLSFAD GKFLRRNDPE CDLCGGDPEK KCHSCSCRVC GGKHEPNMQL
     LCDECNVAYH IYCLNPPLDK VPEEEYWYCP SCKTDSSEVV KAGERLKMSK KKAKMPSAST
     ESRRDWGRGM ACVGRTRECT IVPSNHYGPI PGIPVGSTWR FRVQVSEAGV HRPHVGGIHG
     RSNDGAYSLV LAGGFADEVD RGDEFTYTGS GGKNLAGNKR IGAPSADQTL TNMNRALALN
     CDAPLDDKIG AESRNWRAGK PVRVIRSFKG RKISKYAPEE GNRYDGIYKV VKYWPEISSS
     HGFLVWRYLL RRDDVEPAPW TSEGIERSRR LCLRLQYPAG YPSDKEGKKP KGQSKKQPSG
     TTKRPISDDD CPSASKVYKA SDSAEAIEAF QLTPQQQHLI REDCQNQKLW DEVLSHLVEG
     PNFLKKLEQS FMCVCCQELV YQPVTTECFH NVCKDCLQRS FKAQVFSCPA CRHDLGQNYI
     MIPNEILQTL LDLFFPGYSK GR
//
